Simulations Plus

SLP

Market cap $285M

Simulations Plus, Inc. remains a Hold as business improvement is insufficient to warrant a Buy, despite stabilization post-earnings. Q2 2026 revenue grew 8% YoY to $24.3M, with strong software renewals (91%) and expanding services backlog (+18% YoY). SLP trades at ~14x blended earnings, appearing cheap versus history but still expensive on GAAP metrics given slow revenue and cash flow growth.

Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position.

It notched beats on both revenue and profitability in its fiscal second quarter. On a negative note, it cut its net income forecast for the full fiscal year.

SLP beats fiscal Q2 earnings and posts solid revenue growth, but cuts full-year EPS view even as backlog rises and margins expand across software and services.

Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript

Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, repres.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how n.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, “From Debate to Deployment: Responsible, Practical AI in MIDD,” to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver.